INH A21
Alternative Names: INH-A00021; INHA-21; VeronateLatest Information Update: 11 Jul 2006
At a glance
- Originator Inhibitex
- Class Immunoglobulins; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neonatal infections; Nosocomial infections; Staphylococcal infections
Most Recent Events
- 11 Jul 2006 Review of final results from a phase III clinical trial in very low birth weight infants for the prevention of staphylococcal infections have been added to the Bacterial Infections therapeutic trials section and to the overview section
- 10 Apr 2006 Final results from a phase II clinical trial in very low birth weight infants for the prevention of staphylococcal infections have been added to the adverse events and Bacterial Infections therapeutic trials sections
- 03 Apr 2006 Interim results from a phase III clinical trial in premature infants for the prevention of nosocomial bloodstream infections due to S. aureus have been added to the adverse events and Bacterial Infections therapeutic trials sections